Parafend 2.265% w/v Oral Suspension

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Oxfendazole

Available from:

Norbrook Laboratories Limited

ATC code:

QP52AC02

INN (International Name):

Oxfendazole

Pharmaceutical form:

Oral suspension

Prescription type:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Therapeutic group:

Sheep

Therapeutic area:

Anthelmintic

Authorization status:

Expired

Authorization date:

1994-07-27

Summary of Product characteristics

Revised: August 2010
(Amended pages)
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Parafend 2.265% w/v Oral suspension
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
The active ingredient of Parafend is Oxfendazole 2.265 % w/v
EXCIPIENTS:
Sodium methyl parahydroxybenzoate 1.8 mg/ml as an antimicrobial
preservative and Sodium metabisulphite 1.5 mg/ml as antioxidant
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral Suspension
An off white to white suspension
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Sheep
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
A broad spectrum anthelmintic for the control of mature and developing
immature gastro-intestinal roundworms and lungworms and also tapeworms
in sheep. Ovicidal for strongyle eggs.
For the treatment of sheep infested with benzimidazole susceptible
strains of
the following species:
GASTROINTESTINAL ROUNDWORMS:
_Ostertagia_ spp, _Haemonchus_ spp, _Nematodirus_ spp,
_Trichostrongylus_ spp,
_Cooperia_ spp, _Oesophagostomum_ spp and _Chabertia_ spp.
Also provides useful control of _Trichuris _spp.
LUNGWORMS:
_Dictyocaulus_ spp
Revised: August 2010
(Amended pages)
Page 2 of 6
TAPEWORMS:
_Moniezia_ spp
In sheep it is also effective against inhibited/arrested larvae of
_Nematodirus_
spp and benzimidazole susceptible _Haemonchus_ spp and _Ostertagia_
spp.
4.3
CONTRAINDICATIONS
None
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase
the risk of development of resistance and could ultimately result in
ineffective
therapy:
•
Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
•
Under dosing, which may be due to underestimation of body weight,
misadministration of the product, or lack of calibration of the dosing
device (if any)
Suspected clinical cases of resistance to anthelmintics should be
further
investigated using appropriate tests (e.g. Faecal Egg Count Reduct